Insurers Oppose Spreading Patient Costs In Medicare Part D Over Time

By Rachel Cohrs
October 10, 2019 at 2:27 PM
Updated Story Drug makers are lobbying the Senate Finance Committee to allow patients to pay out-of-pocket costs over time in the Finance Committee’s Part D redesign, but insurers oppose the idea because they would have to pay up-front costs, according to several sources familiar with the lobbying efforts. Under the Senate Finance drug pricing proposal, beneficiaries’ out-of-pocket costs would be capped at $3,100 starting in 2022. Drug makers want to add a provision to the bill that...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.